| 杨洋,夏豪,刘浙波,等.早期应用替罗非班对急性心肌梗死冠脉多支病变经皮冠状动脉介入术后患者临床疗效观察[J].安徽医药,2016,20(11):2139-2142. |
| 早期应用替罗非班对急性心肌梗死冠脉多支病变经皮冠状动脉介入术后患者临床疗效观察 |
| Clinical effect observation for early tirofiban application in acute myocardial infarction patients with multi-vessel coronary artery disease undergoing percutaneous coronary intervention |
| 投稿时间：2016-07-05 |
| DOI： |
| 中文关键词: 替罗非班 急性心肌梗死 多支病变 经皮冠状动脉介入术 |
| 英文关键词: Tirofiban Acute myocardial Infarction Multivesseldiseaes PCI |
| 基金项目:国家自然科学基金资助项目( 81270184)作者简介:杨洋,女,硕士研究生 |
|
| 摘要点击次数: 2899 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 探讨替罗非班用于急性心肌梗死冠脉多支病变行经皮冠状动脉介入术(PCI)治疗的有效性及安全性。方法 选取行PCI的急性心肌梗死多支病变患者196例,根据术前是否使用替罗非班,将患者分为替罗非班组(观察组,84例)和非替罗非班组(对照组,112例)。替罗非班组在术前常规治疗的基础上加用替罗非班,而对照组未加用。术后均对患者随访6个月,统计两组患者基本临床资料、冠脉病变特征、药物使用情况,分析随访期间主要不良心血管事件(死亡、再梗死、靶血管血运重建)发生情况、不良反应发生率。结果 在基本临床资料、冠脉病变特征、药物使用情况的统计中两组比较,差异无统计学意义(P>0.05),具有可比性。随访期间(6个月内)MACE发生率观察组较对照组降低,差异有统计学意义(P＜0.05)。临床出血并发症及总不良反应发生率差异无统计学意义(P＞0.05)。结论 急性心肌梗死多支病变的患者早期应用替罗非班,可有效降低MACE的发生率,改善临床预后,且不增加出血并发症发生率具有良好的安全性,值得临床应用和推广。 |
| 英文摘要: |
| Objective To evaluate theefficacy and safety of tirofiban in treatment of patientssuffering from acute myocardial infarction with multivessel diseases undergoing percutaneous coronary intervention.Methods A total of 196 patients of acute myocardial infarction with multi-vessel coronary artery disease who received PCI were randomized into tirofiban group(observation group,n=84)and non-tirofiban group(control group,n=112)according to whether or not tirofiban was used during PCI procedure.The observationgroup usedtirofibanon the basis of preoperative conventional treatment,while thecontrol groupdidnot usetirofiban.Basic clinical data,laboratory results,therapeutic use of drugs,coronary artery disease characteristics and major adverse cardiovascular events during the 6-monthfollow-up and bleeding complications were observed and compared betweenthe two groups.Results There were no statistically significant differences in basic clinical data,therapeutic use of drugs and coronary artery disease characteristics between the two groups(P＞0.05).During the 6-month follow-up,the incidence of MACE in the observation group was significantly lower than that of controlgroup(P＜0.05).There were no significant differences in adverse reaction and clinical bleeding complications(P＞0.05).Conclusions Early tirofiban application can effectively reduceincidence of MACE on patients suffering from acute coronary syndrome with multivessel diseases undergoing percutaneous coronary intervention,and there is no increase in bleeding complications.Therefore,tirofiban is an effectiveand safe antiplatelet drug in the treatment of AMI. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
